In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 439 for your search:

Drug:  oxaliplatin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676

OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21380, NCT00577031

Phase II/III Randomized Study of Fluorouracil/Leucovorin with vs without Oxaliplatin for Inoperable Metastatic Colorectal Cancer (Summary Last Modified 03/98)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: FRE-DEB95-OXA-01, EU-96023

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 04458, P30CA082103, UCSF-04458, NCT00227617

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000453890, GERCOR-OPTIMOX2, GERCOR-OPTIMOX2-2003, GERCOR-OPTIMOX2-C02-2, EU-20566, SANOFI-GERCOR-OPTIMOX2, NCT00274872

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00051, EUDRACT No 2006-001194-14, HORIZON II, NCT00399035

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595050, FRE-FNCLCC- ACCORD-17-0707, EU-20848, NCT00861094

10.

Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras, BRAF Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III, Phase II
Type: Diagnostic, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, ISRCTN83171665, EU-20960, NCT00975897

11.

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560

12.

Early Commencement of Adjuvant Chemotherapy for Colon Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Enrolling by invitation
Age: 18 to 70
Sponsor: Other
Protocol IDs: KNUHCRC004, NCT01460589

13.

Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000066151, FRE-GERCOR-C97-3/CPTF308, FRE-C97-3/CPTF301, FRE-C97-3/CPTF308, RP-FRE-C97-3/CPTF308, EU-97044, NCT00003260

14.

Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-05963, NCT00003287

15.

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066665, NCCTG-N9741, CAN-NCIC-CO13, CLB-89804, E-N9741, SWOG-N9741, N9741, CO13, NCT00003594

16.

Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01847, N9841, SWOG-N9841, NCCTG-N9841, CDR0000067623, ECOG-N9841, U10CA025224, NCT00005036

17.

Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000068282, FRE-GERCOR-OPTIMOX-2000, EU-20034, NCT00006468

18.

Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000068309, EORTC-40983, AGITG-EORTC-40983, ALM-CAO-EORTC-40983, CRUK-LON-EORTC-40983, FFCD-EORTC-40983, EU-20048, CRC-EORTC-40983, NCT00006479

19.

Phase III Randomized Study of Fluorouracil With Leucovorin Calcium and Either Irinotecan or Oxaliplatin in Patients With Unresectable Metastatic Colorectal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MRC-CR08-FOCUS, EU-20038, ISRCTN79877428, NCT00008060

20.

Phase III Randomized Study of Fluorouracil and Leucovorin Calcium Versus Oxaliplatin Alone Versus Fluorouracil, Leucovorin Calcium, and Oxaliplatin in Patients With Metastatic Colorectal Carcinoma (Summary Last Modified 04/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SANOFI-EFC4584, BRCC-00036, NCT00008281

21.

Phase III Randomized Study of Irinotecan With or Without Oxaliplatin in Patients With Metastatic Colorectal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SANOFI-EFC4585, NCT00012389

22.

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02417, E3200, U10CA021115, CDR0000068951, NCT00025337

23.

Phase III Randomized Study of Prolonged Infusion Gemcitabine With Versus Without Oxaliplatin Versus Standard Infusion Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-6201, E6201, NCT00058149

24.

Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NSABP R-04, CALGB-NSABP-R-04, NCT00058474

25.

Phase III Randomized Study of Oxaliplatin and Bevacizumab (Avastin™) With Fluorouracil and Leucovorin Calcium or Capecitabine in Patients With Advanced Colorectal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PROLOGUE-SANOFI-ARD5099, SANOFI-ARD5099, NCT00062426

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map